Summary Activating ras mutations are found in many types of human tumour. Mutations in Harvey (H-). Kirsten (K-) and neuronal (N-) ras are, however, rarely found in breast carcinomas. TC21 is a ras family member that shares close homology to H-. K-and N-ras. and (N) -ras w-ere the first to be identified. and are the most w-ell-characterized w-ith respect to mutational status in tumours. There is a large X ariation in the frequency of mutations betw een tumour tx pes. The hinhest incidence thus found is in pancreatic tumours. where over 80% hax-e mutated K-ras genes. w%-hereas mutations are rarely seen in either H-. K-or N-ras in breast tumours (Bos. 1989: Clark-and Der. 1995. Ras mutations hax-e been described in some mucinous
Accepted 28 January 1998 Correspondence to: KT Barker oxarian cancers (Ichikaxxa et al. 1994 : Cuatrecasas et al. 1997 . but generally appear to be a rare ex-ent in ox-arian carcinomas xvan t Veer et al. 1988: Berchuck and Carnev. 1997) . The incidence in cerv ical cancer is not as clear. some reports describe a high frequency of ras mutations (Riou et al. 1988 : Wong et al. 1995 . others haxe found a verx lowx frequencv (Bos. 1988 : Willis. 1993 .
One possible explanation for the absence of ras mutations in breast cancer could be that deregulation of RAS function does not lead to uncontrolled growth of breast epithelial cells. Human phaeochromocytomas do not haxe mutations in ras. and the introduction of oncogenic RAS into PC 12 cells. w-hich are rat phaeochromocytoma cells. leads to differentiation and groxxth arrest (Bar-Sagi and Feramisco. 1985: Noda et al. 1985) . This does not appear to be the case for breast epithelial cells. For example. expression of oncogenic H-ras leads to the transformation of the breast epithelial cell line MCF 1OA (Basolo et al. 1991 ). Elex ated lexvels of H-ras product have been detected in human breast tumours (Watson et al. 1990 ). Another possibility is that deregulation of RAS pathways xia other mechanisms not inxolxing mutations in ras genes may be important. Alternatixely. other members of the ras family may play more major roles in growth control in breast cancer. and mutations may be found in these genes. TC2 1 is a ras family member cloned from a human teratocarcinoma cell line. It shoxws overall 60%' nucleotide and 55%1c amino acid identity w-ith H-. K-and N-ras. xith a strictly conserxed effector domain . This is the closest homoloax to H-. K-and N-ras genes of any of the ras superfamilx cloned to date. There are sexeral pieces of exidence to suggest that TC2 1 may play a role in human cancer. Codons 22. 23 and 72 in TC21 are analogous to those A-hose in xvixo mutation leads to oncogenic actixation in H-. K-and N-ras (Graham et al. 1994) . Ahen codons 22 and 72 wxere experimentally mutated in TC2 1. 22 Glu to Val. and 72 Gln to Leu. the result w as a transforming actixvitx equivalent to that of oncogen c ras (Graham et al. 1994 . A form of the 72 Gln to Leu mutation in TC2 1 has been cloned from an ox arian carcinoma cell line (Chan et al. 1994) . and the transforming capacity and tumongenicity of this mutation in NIH/3T3 cells was confirmed. An insertional mutation of 9 bp at codon 24 in TC21 has been identified in a human leiomyosarcoma cell line. and this displays high transforming activity in NlH/3T3 cells (Huang et al, 1995 spontaneously immortalized human mammary epithelial cells (Soule et al. 1990 ). causing altered cell morphology and allowing colony formation in soft agar (Clark et al, 1996) . It 
MATERIALS AND METHODS SSCP
RNA was isolated using the RNAgents® Total RNA Isolation System (Promega). by a modification of the method of Wilkinson ( 1988) or using guanidinium isothiocyanate (Chirgwin et al. 1979) . cDNA was prepared as described previously (Barker et al. 1995 [3n-P] dCTP. Amplified products were resolved on 1.5% agarose TAE gels, excised and purified using a QLAEX H Gel Extraction Kit (Qiagen). Purified products were subcloned into the pGEMI-T Easy vector (Promega) according to the manufacturer's instructions. Sequences were determined by the dideoxy method of Amplified products were purified using a QIAEX II Gel Extraction Kit. Sequence reactions using a Sequenase Version 2.0 Kit (USB) were performed on approximately 30 ng of purified product and an excess of primer (1 ig 10 jl ').
RESULTS

SSCP analysis of breast cancer cell lines
The genomic structure of TC21 has not yet been reported. therefore mutation analysis was performed on cDNA. Primers that bracket the region containing all three potential activating mutation sites were used to amplify a single band of the predicted size by PCR. SSCP gel running conditions that detect an altered mobility caused by a single base pair change were assessed using cDNA from normal mammary tissue. and from the ovarian cell line A2780. which has an A-T transversion in codon 72 leading to British Journal of Cancer (1998) shows wild-type sequence, CAA (gin), CAL51 reveals a mutabon CTA (leu) a Gin to Leu mutation (Chan et al. 1994) (Figure IA) . Two bands representing two complementary strands were observed, and there was a shift in mobility of the higher band in the A2780-derived PCR product compared with the normal tissue as expected (Huang et al. 1995) . Ten breast carcinoma cell lines were examined (Figure lB 
TC21 is mutated in CAL51 cells
To investigate the cause of the shift in mobility seen in the SSCP analysis of CAL51 cell line cDNA. the sequence of the derived PCR product was determined. An A to T base change in codon 72. causing a predicted Gln-Leu mutation identical to that seen in the cell line A2780. was seen. Figure 2 shows Figure 3 shows a representative sample. whereas one product produced an apparently altered pattern. This cDNA and one obviously normal cDNA were amplified by PCR and sequenced. Sequencing of the product from one node revealed some silent changes with respect to the published cDNA sequence. but none resulting in amino acid changes.
DISCUSSION
The low frequency of H-. K-and N-ras mutations in breast tumours has led us to undertake this study to examine the possibility that the ras superfamily member TC2 1 is mutated in breast cancers. None of the nine primary or 15 metastatic breast carcinoma samples that we analysed were mutant for TC21. We conclude that TC2 1 mutations are an infrequent event in the development of breast tumours. Of the panel of breast. ovarian and cervical cancer cell lines analysed, only one. the breast carcinoma cell line CAL5 1, had a mutation in TC2 1. CALS 1 cells were isolated from a malignant pleural effusion of a woman with a metastatic breast adenocarcinoma. The cells exhibit morphological. structural and immunohistochemical characteristics of mammary epithelial cells. They will form colonies in soft agar and are tumorigenic in nude mice (Gioanni et al. 1990) . Unlike the majority of established breast carcinoma cell lines they have an apparently normal karyotype (Gioanni et al. 1990; S Birdsall. personal communication) . The genetic alterations responsible for the neoplastic phenotype of CAL5 1 are not known (they lack mutations in the p53 gene. Theile et al. 1994 ). To our knowledge. this British Joumal of Cancer (1998) 78(3), 296-300
mutation in TC2 1 is the onl-genetic aberration reported for CAL5 1 cells. Ahen this mutant form (72. Gln-Leu) was transfected into MICF1OA cells. it conferred the abilitv to form colonies in soft a2ar. but not tumorigenicitv in nude mice (Clar-k et al. 1996) . It is possible that the ability of CAL5 1 cells to form colonies in soft agar is at least partially due to this mutation in TC2 1.
Mutations in ras genes do not appear to be a common event in breast. cervical or ovarian tumours (with the possible exception of mucinous ovarian tumours. see Introduction). Although it could be hypothesized that cell type-specific differences in the likelihood of acquiring co-operating mutations account for the apparent tumour type bias of ras mutations. the deregulation of RAS pathways in the development of tumours such as those of the breast should not be discounted. Activated RAS is able to transform breast epithelial cells (Basolo et al. 1991) . and chemicallv induced rat mammary tumours harbour ras mutations (Sukumar. 1990). Human breast epithelial cells transformed by carcinogens acquire activatingy ras mutations (Zhang et al. 1994 ). In addition. several studies in transgenic mice have found that activated and/or overexpressed ras alleles can predispose to the development of mammary tumours (Andres et al. 1987: Sinn et Bollag et al. 1996 : Guha et al. 1996 . NFl mutations have also been found to occur in spontaneously arising tumours (Li et al. 1992 : Andersen et al. 1993) . However. some cell lines established from tumours occumn2 in non-NFl patients have reduced levels of NFl but not elevated RAS-GTP levels (Johnson et al. 1993) . It may be that loss of NT1 function(s) independent from GAP activitv play a role in the phenotype of these cells. It is hypothesized that GAPs may function as downstream effectors of RAS in addition to their regulatory activity (Clark and Der. 1995) .
There have been cases of breast cancers of an aggressive nature reported in NFl patients (Teh et al. 1997) . It may therefore prove informative to make a more detailed analyNsis of NF l or p12O GAP expression and sequence in breast and other tumours.
